aluates Reports

$ 0.0

Automative

Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Research Report 2025

Published Date: January 2025

Report Code: QYRE-Auto-37Q13823

Global B Cell Maturation Antigen BCMA Targeted Therapies Market Insights Forecast to 2029

BUY CHAPTERS

Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Research Report 2025

Code: QYRE-Auto-37Q13823

Report

January 2025

Pages:86

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Transposagen Biopharmaceuticals

Sutro Biopharma

Malin Corporation

Eureka Therapeutics

firstVentury Equity

Five Prime Therapeutics

Credit Suisse Securities

Dana-Farber Cancer Institute

Deerfield Partners

Onyx Pharmaceuticals

Juno Therapeutics

B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

The global market for B-Cell Maturation Antigen (BCMA) Targeted Therapies was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for B-Cell Maturation Antigen (BCMA) Targeted Therapies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding B-Cell Maturation Antigen (BCMA) Targeted Therapies.

The B-Cell Maturation Antigen (BCMA) Targeted Therapies market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global B-Cell Maturation Antigen (BCMA) Targeted Therapies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the B-Cell Maturation Antigen (BCMA) Targeted Therapies companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report

Report Metric	Details
Report Name	B-Cell Maturation Antigen (BCMA) Targeted Therapies Market
CAGR	5%
Segment by Type	Bispecific Antibodies Antibody Drug Conjugates Chimeric Antigen Receptor T-Cells
Segment by Application	Liver Cancer Respiratory Cancer Brain Cancer Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Transposagen Biopharmaceuticals, Sutro Biopharma, Malin Corporation, Eureka Therapeutics, firstVentury Equity, Five Prime Therapeutics, Credit Suisse Securities, Dana-Farber Cancer Institute, Deerfield Partners, Onyx Pharmaceuticals, Juno Therapeutics
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of B-Cell Maturation Antigen (BCMA) Targeted Therapies company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market report?

Ans: The main players in the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market are Transposagen Biopharmaceuticals, Sutro Biopharma, Malin Corporation, Eureka Therapeutics, firstVentury Equity, Five Prime Therapeutics, Credit Suisse Securities, Dana-Farber Cancer Institute, Deerfield Partners, Onyx Pharmaceuticals, Juno Therapeutics

What are the Application segmentation covered in the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market report?

Ans: The Applications covered in the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market report are Liver Cancer, Respiratory Cancer, Brain Cancer, Others

What are the Type segmentation covered in the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market report?

Ans: The Types covered in the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market report are Bispecific Antibodies, Antibody Drug Conjugates, Chimeric Antigen Receptor T-Cells

Recommended Reports

Lymphoma & Hematologic Therapies

Cell & Immuno Therapies

Oncology Targeted Drugs

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Bispecific Antibodies

1.2.3 Antibody Drug Conjugates

1.2.4 Chimeric Antigen Receptor T-Cells

1.3 Market by Application

1.3.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Liver Cancer

1.3.3 Respiratory Cancer

1.3.4 Brain Cancer

1.3.5 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Perspective (2020-2031)

2.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Growth Trends by Region

2.2.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Historic Market Size by Region (2020-2025)

2.2.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecasted Market Size by Region (2026-2031)

2.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Dynamics

2.3.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Industry Trends

2.3.2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Drivers

2.3.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Challenges

2.3.4 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top B-Cell Maturation Antigen (BCMA) Targeted Therapies Players by Revenue

3.1.1 Global Top B-Cell Maturation Antigen (BCMA) Targeted Therapies Players by Revenue (2020-2025)

3.1.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Players (2020-2025)

3.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue

3.4 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Concentration Ratio

3.4.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue in 2024

3.5 Global Key Players of B-Cell Maturation Antigen (BCMA) Targeted Therapies Head office and Area Served

3.6 Global Key Players of B-Cell Maturation Antigen (BCMA) Targeted Therapies, Product and Application

3.7 Global Key Players of B-Cell Maturation Antigen (BCMA) Targeted Therapies, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 B-Cell Maturation Antigen (BCMA) Targeted Therapies Breakdown Data by Type

4.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Historic Market Size by Type (2020-2025)

4.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecasted Market Size by Type (2026-2031)

5 B-Cell Maturation Antigen (BCMA) Targeted Therapies Breakdown Data by Application

5.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Historic Market Size by Application (2020-2025)

5.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (2020-2031)

6.2 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2020-2025)

6.4 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (2020-2031)

7.2 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2020-2025)

7.4 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (2020-2031)

8.2 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (2020-2025)

8.4 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (2020-2031)

9.2 Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2020-2025)

9.4 Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (2020-2031)

10.2 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2020-2025)

10.4 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Transposagen Biopharmaceuticals

11.1.1 Transposagen Biopharmaceuticals Company Details

11.1.2 Transposagen Biopharmaceuticals Business Overview

11.1.3 Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction

11.1.4 Transposagen Biopharmaceuticals Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025)

11.1.5 Transposagen Biopharmaceuticals Recent Development

11.2 Sutro Biopharma

11.2.1 Sutro Biopharma Company Details

11.2.2 Sutro Biopharma Business Overview

11.2.3 Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction

11.2.4 Sutro Biopharma Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025)

11.2.5 Sutro Biopharma Recent Development

11.3 Malin Corporation

11.3.1 Malin Corporation Company Details

11.3.2 Malin Corporation Business Overview

11.3.3 Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction

11.3.4 Malin Corporation Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025)

11.3.5 Malin Corporation Recent Development

11.4 Eureka Therapeutics

11.4.1 Eureka Therapeutics Company Details

11.4.2 Eureka Therapeutics Business Overview

11.4.3 Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction

11.4.4 Eureka Therapeutics Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025)

11.4.5 Eureka Therapeutics Recent Development

11.5 firstVentury Equity

11.5.1 firstVentury Equity Company Details

11.5.2 firstVentury Equity Business Overview

11.5.3 firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction

11.5.4 firstVentury Equity Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025)

11.5.5 firstVentury Equity Recent Development

11.6 Five Prime Therapeutics

11.6.1 Five Prime Therapeutics Company Details

11.6.2 Five Prime Therapeutics Business Overview

11.6.3 Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction

11.6.4 Five Prime Therapeutics Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025)

11.6.5 Five Prime Therapeutics Recent Development

11.7 Credit Suisse Securities

11.7.1 Credit Suisse Securities Company Details

11.7.2 Credit Suisse Securities Business Overview

11.7.3 Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction

11.7.4 Credit Suisse Securities Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025)

11.7.5 Credit Suisse Securities Recent Development

11.8 Dana-Farber Cancer Institute

11.8.1 Dana-Farber Cancer Institute Company Details

11.8.2 Dana-Farber Cancer Institute Business Overview

11.8.3 Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction

11.8.4 Dana-Farber Cancer Institute Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025)

11.8.5 Dana-Farber Cancer Institute Recent Development

11.9 Deerfield Partners

11.9.1 Deerfield Partners Company Details

11.9.2 Deerfield Partners Business Overview

11.9.3 Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction

11.9.4 Deerfield Partners Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025)

11.9.5 Deerfield Partners Recent Development

11.10 Onyx Pharmaceuticals

11.10.1 Onyx Pharmaceuticals Company Details

11.10.2 Onyx Pharmaceuticals Business Overview

11.10.3 Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction

11.10.4 Onyx Pharmaceuticals Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025)

11.10.5 Onyx Pharmaceuticals Recent Development

11.11 Juno Therapeutics

11.11.1 Juno Therapeutics Company Details

11.11.2 Juno Therapeutics Business Overview

11.11.3 Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction

11.11.4 Juno Therapeutics Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025)

11.11.5 Juno Therapeutics Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Transposagen Biopharmaceuticals

Sutro Biopharma

Malin Corporation

Eureka Therapeutics

firstVentury Equity

Five Prime Therapeutics

Credit Suisse Securities

Dana-Farber Cancer Institute

Deerfield Partners

Onyx Pharmaceuticals

Juno Therapeutics

List of Tables

Table 1. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Bispecific Antibodies

Table 3. Key Players of Antibody Drug Conjugates

Table 4. Key Players of Chimeric Antigen Receptor T-Cells

Table 5. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (2020-2025) & (US$ Million)

Table 8. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Region (2020-2025)

Table 9. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 10. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Region (2026-2031)

Table 11. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Trends

Table 12. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Drivers

Table 13. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Challenges

Table 14. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Restraints

Table 15. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Players (2020-2025) & (US$ Million)

Table 16. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Players (2020-2025)

Table 17. Global Top B-Cell Maturation Antigen (BCMA) Targeted Therapies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies as of 2024)

Table 18. Ranking of Global Top B-Cell Maturation Antigen (BCMA) Targeted Therapies Companies by Revenue (US$ Million) in 2024

Table 19. Global 5 Largest Players Market Share by B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (CR5 and HHI) & (2020-2025)

Table 20. Global Key Players of B-Cell Maturation Antigen (BCMA) Targeted Therapies, Headquarters and Area Served

Table 21. Global Key Players of B-Cell Maturation Antigen (BCMA) Targeted Therapies, Product and Application

Table 22. Global Key Players of B-Cell Maturation Antigen (BCMA) Targeted Therapies, Date of Enter into This Industry

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Type (2020-2025) & (US$ Million)

Table 25. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Type (2020-2025)

Table 26. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 27. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Type (2026-2031)

Table 28. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application (2020-2025) & (US$ Million)

Table 29. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Application (2020-2025)

Table 30. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 31. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Application (2026-2031)

Table 32. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 33. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2020-2025) & (US$ Million)

Table 34. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2026-2031) & (US$ Million)

Table 35. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 36. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2020-2025) & (US$ Million)

Table 37. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2026-2031) & (US$ Million)

Table 38. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 39. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (2020-2025) & (US$ Million)

Table 40. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (2026-2031) & (US$ Million)

Table 41. Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 42. Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2020-2025) & (US$ Million)

Table 43. Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2026-2031) & (US$ Million)

Table 44. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 45. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2020-2025) & (US$ Million)

Table 46. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2026-2031) & (US$ Million)

Table 47. Transposagen Biopharmaceuticals Company Details

Table 48. Transposagen Biopharmaceuticals Business Overview

Table 49. Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Product

Table 50. Transposagen Biopharmaceuticals Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025) & (US$ Million)

Table 51. Transposagen Biopharmaceuticals Recent Development

Table 52. Sutro Biopharma Company Details

Table 53. Sutro Biopharma Business Overview

Table 54. Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Product

Table 55. Sutro Biopharma Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025) & (US$ Million)

Table 56. Sutro Biopharma Recent Development

Table 57. Malin Corporation Company Details

Table 58. Malin Corporation Business Overview

Table 59. Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Product

Table 60. Malin Corporation Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025) & (US$ Million)

Table 61. Malin Corporation Recent Development

Table 62. Eureka Therapeutics Company Details

Table 63. Eureka Therapeutics Business Overview

Table 64. Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product

Table 65. Eureka Therapeutics Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025) & (US$ Million)

Table 66. Eureka Therapeutics Recent Development

Table 67. firstVentury Equity Company Details

Table 68. firstVentury Equity Business Overview

Table 69. firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Product

Table 70. firstVentury Equity Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025) & (US$ Million)

Table 71. firstVentury Equity Recent Development

Table 72. Five Prime Therapeutics Company Details

Table 73. Five Prime Therapeutics Business Overview

Table 74. Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product

Table 75. Five Prime Therapeutics Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025) & (US$ Million)

Table 76. Five Prime Therapeutics Recent Development

Table 77. Credit Suisse Securities Company Details

Table 78. Credit Suisse Securities Business Overview

Table 79. Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Product

Table 80. Credit Suisse Securities Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025) & (US$ Million)

Table 81. Credit Suisse Securities Recent Development

Table 82. Dana-Farber Cancer Institute Company Details

Table 83. Dana-Farber Cancer Institute Business Overview

Table 84. Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Product

Table 85. Dana-Farber Cancer Institute Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025) & (US$ Million)

Table 86. Dana-Farber Cancer Institute Recent Development

Table 87. Deerfield Partners Company Details

Table 88. Deerfield Partners Business Overview

Table 89. Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Product

Table 90. Deerfield Partners Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025) & (US$ Million)

Table 91. Deerfield Partners Recent Development

Table 92. Onyx Pharmaceuticals Company Details

Table 93. Onyx Pharmaceuticals Business Overview

Table 94. Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Product

Table 95. Onyx Pharmaceuticals Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025) & (US$ Million)

Table 96. Onyx Pharmaceuticals Recent Development

Table 97. Juno Therapeutics Company Details

Table 98. Juno Therapeutics Business Overview

Table 99. Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product

Table 100. Juno Therapeutics Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025) & (US$ Million)

Table 101. Juno Therapeutics Recent Development

Table 102. Research Programs/Design for This Report

Table 103. Key Data Information from Secondary Sources

Table 104. Key Data Information from Primary Sources

Table 105. Authors List of This Report

List of Figures

Figure 1. B-Cell Maturation Antigen (BCMA) Targeted Therapies Picture

Figure 2. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Type: 2024 VS 2031

Figure 4. Bispecific Antibodies Features

Figure 5. Antibody Drug Conjugates Features

Figure 6. Chimeric Antigen Receptor T-Cells Features

Figure 7. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application (2020-2031) & (US$ Million)

Figure 8. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Application: 2024 VS 2031

Figure 9. Liver Cancer Case Studies

Figure 10. Respiratory Cancer Case Studies

Figure 11. Brain Cancer Case Studies

Figure 12. Others Case Studies

Figure 13. B-Cell Maturation Antigen (BCMA) Targeted Therapies Report Years Considered

Figure 14. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 15. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Region: 2024 VS 2031

Figure 17. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Players in 2024

Figure 18. Global Top B-Cell Maturation Antigen (BCMA) Targeted Therapies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies as of 2024)

Figure 19. The Top 10 and 5 Players Market Share by B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue in 2024

Figure 20. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Country (2020-2031)

Figure 22. United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Country (2020-2031)

Figure 26. Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. France B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. U.K. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Nordic Countries B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Region (2020-2031)

Figure 34. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Southeast Asia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Country (2020-2031)

Figure 42. Mexico B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Country (2020-2031)

Figure 46. Turkey B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Saudi Arabia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. UAE B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Transposagen Biopharmaceuticals Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025)

Figure 50. Sutro Biopharma Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025)

Figure 51. Malin Corporation Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025)

Figure 52. Eureka Therapeutics Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025)

Figure 53. firstVentury Equity Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025)

Figure 54. Five Prime Therapeutics Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025)

Figure 55. Credit Suisse Securities Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025)

Figure 56. Dana-Farber Cancer Institute Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025)

Figure 57. Deerfield Partners Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025)

Figure 58. Onyx Pharmaceuticals Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025)

Figure 59. Juno Therapeutics Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2020-2025)

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Therapeutic BCG Vaccines Market Insights Forecast to 2030

Global Immune Drugs Market Insights Forecast to 2030

Tumor Immunotherapy Market

Global Fermented BCAA Market Research Report 2025

Global Chimeric Antigen Receptor Cell Therapy Market Research Report 2024

Global BNCT Boron Drug Market Research Report 2025

Global CAR T Cellular Immunotherapy Drug Market Research Report 2024

Next Generation Immunology Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Cancers Immunotherapy Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Targeted Drugs for Multiple Myeloma Market Research Report 2024

Cutaneous B Cell Lymphoma Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Lymphoma Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Antibody Drug Conjugate Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Lymphoma Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Cell Therapy Technologies Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Next Generation Antibody Drug Market Research Report 2024

Cutaneous Cell Lymphoma Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Myeloid Cells Targeting Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Image Guided Therapy Devices Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Geriatric Care Services Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-17Q6174

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Hospice Software Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-8Z4276

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Geriatric Care Devices Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-8Q8325

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Allied Health Care Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-29V19536

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions